GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
- First Posted Date
- 2014-12-15
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02316509
- Locations
- 🇺🇸
Massachusetts General Hospital., Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Spain
A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT02311894
- Locations
- 🇺🇸
Barry J Reiner, MD, LLC, Baltimore, Maryland, United States
🇺🇸Endocrine Associates of Dallas, Dallas, Texas, United States
🇺🇸Miami Children's Hospital, Miami, Florida, United States
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT02301988
- Locations
- 🇪🇸
Hospital Universitario Virgen Macarena, Seville, Sevilla, Spain
🇺🇸Arizona Oncology Associates, PC-CASA, Tucson, Arizona, United States
🇺🇸Rocky Mountain Cancer Center - Lakewood (West), Lakewood, Colorado, United States
A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02300025
A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2018-06-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT02293863
- Locations
- 🇲🇽
CEPREP; Hospital Universitario, Monterrey, Mexico
🇵🇱Oddział Anestezjologii i Intensywnej Terapii Wojewódzki Specjalistyczny Szpital im dr Wł Biegańsk, Łódź, Poland
🇧🇬MHAT "Dr. Tota Venkova"- Gabrovo, Gabrovo, Bulgaria
A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT02288559
- Locations
- 🇺🇸
Retinal Diagnostic Center, Campbell, California, United States
🇺🇸The Retina Partners, Encino, California, United States
🇺🇸Loma Linda University, Loma Linda, California, United States
A Study of High Dose MHAA4549A in Healthy Volunteers
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02284607
- Locations
- 🇨🇦
inVentiv Health Clinique, Quebec, Canada
A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 334
- Registration Number
- NCT02273973
- Locations
- 🇦🇹
Lkh-Univ. Klinikum Graz; Klinik Für Gynäkologie, Graz, Austria
🇧🇪Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇭🇺Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika, Debrecen, Hungary
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT02271139
- Locations
- 🇺🇸
LAC USC Medical Center, Los Angeles, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States
A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 174
- Registration Number
- NCT02219724
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇺🇸University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States